Clinical trials: Psoriasis Arthritis
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Psoriatic Arthritis, Ultrasound Assessment
Apremilast and Adalimumab in Psoriatic Arthritis Patients
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
- Conditions
- Psoriatic Arthritis, Ultrasound Assessment, TNF
- Trial name
- NCT07398651
- Testing
- Adalimumab, Apremilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Rheumatoid Arthritis, Psoriatic Arthritis
Mindfulness Based Stress Reduction in Rheumatic Diseases
This study will assess the mental health and clinical benefits of Mindfulness Based Stress Reduction (MBSR) in patients with rheumatic disease who have anxiety or depression.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Trial name
- MBSR (NCT03411057)
- Testing
- Mindfulness Based Stress Reduction (MBSR), Control
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- Trial name
- NCT06624228
- Testing
- Bimekizumab, Risankizumab
- Where
- 127 sites in United States, Australia and 9 more
- Volunteers
- 553 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis, Spondylitis
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
To evaluate the efficacy of Tofacitinib in reducing inflammation in the sacroiliac joints and spine on magnetic resonance imaging (MRI) in patients with active Psoriatic Arthritis (PsA) with axial Involvement (BASDAI [Bath…
- Conditions
- Psoriatic Arthritis, Spondylitis, Sacroilitis
- Trial name
- PASTOR (NCT04062695)
- Testing
- Tofacitinib 5 MG Oral Tablet [Xeljanz]
- Where
- 19 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Arthritis, Psoriatic
Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study…
- Trial name
- APPRAISE (NCT03608657)
- Testing
- Apremilast
- Where
- 19 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents
An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT03470688
- Testing
- Originator, Biosimilar
- Where
- 22 sites in Australia
- Volunteers
- 5,000 people
- Sponsor
- Opal Rheumatology Ltd.
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a…
- Trial name
- NCT06870500
- Testing
- Methotrexate
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Valley University
Rheumatoid Arthritis, Lupus Erythematosus, Systemic
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
Fatigue is common and disabling for most patients with inflammatory rheumatic disease. Therapies designed to improve physical activity and 'talking' treatments, which positively help patients change the way they think and behave…
- Conditions
- Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Axial Spondyloarthritis, Psoriatic Arthritis
- Trial name
- LIFT (NCT03248518)
- Testing
- Usual Care, Cognitive behavioural approach, Personalised Exercise Programme
- Where
- 6 sites in United Kingdom
- Volunteers
- 368 people
- Sponsor
- University of Aberdeen
Psoriasis Arthritis
Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
Psoriatic arthritis (PsA) is a chronic musculoskeletal disease that affects 0.1%-1% of the general population and about 20% of patients with psoriasis.
- Trial name
- GUPAIN (NCT06974474)
- Testing
- Guselkumab
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Psoriatic Arthritis, Enthesitis
EBIO - Enthesitis Biopsy Study
The purpose of this Phase IV study is to determine the effect of secukinumab on total immune cell numbers obtaines by entheseal biopsy in the inflamed human entheses in patients with Psoriatic Arthritis.
- Conditions
- Psoriatic Arthritis, Enthesitis, Biopsy
- Trial name
- EBIO (NCT04887597)
- Testing
- Secukinumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis
The MEDIPSA Clinical Trial
The main purpose of this study is to validate the positive effect of "Omnibiotic Stress Repair" on patients with active psoriatic Arthritis.
- Trial name
- MEDIPSA (NCT04588623)
- Testing
- Omnibiotic Stress Repair (OBSR)
- Where
- Austria
- Volunteers
- 66 people
- Sponsor
- Medical University of Graz
Psoriatic Arthritis
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active PsA.
- Trial name
- NCT03320876
- Testing
- filgotinib
- Where
- 25 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 122 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active…
- Trial name
- NCT07406035
- Testing
- TQH3906 Capsule, Tofacitinib Citrate Tablet 5 mg
- Where
- 44 sites in China
- Volunteers
- 156 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Psoriatic Arthritis, Psoriasis
Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in…
- Conditions
- Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes
- Trial name
- PLAQUE (NCT02472717)
- Testing
- liraglutide
- Where
- Canada
- Sponsor
- University Health Network, Toronto